# A Simple Machine Learning Framework to Aid Citation Screening in Systematic Reviews and Meta-Analyses of Aging and Longevity Research Studies

Marko Lalović March 10, 2021




Figure 1: General overview of proposed framework.

1/16

# **Background**

- A systematic review typically addresses a specific clinical question by collecting and analyzing data from all the relevant and unbiased set of studies.
- Citation screening is the first yet tedious task of narrowing down the large set of citations retrieved via a broad database query to those relevant for the review.

### Idea

Develop a machine learning framework to semi-automate citation screening in systematic reviews and meta-analyses, thereby reducing reviewers workload (and screening errors).

### **Related Work**

- Wallace et al. developed a semi-automated citation screening algorithm for systematic reviews of biomedical literature.
- Bannach-Brown et al. described their approaches to aid citation screening for a systematic review of pre-clinical animal studies.
- Howard et al. deployed a general software system that automate the required methodologies called "SWIFT-Review".
- Przybyła et.al introduced a web-based software system called "RobotAnalyst".
- O'Mara-Eves et al. performed a systematic review of current approaches.
- To date, no use of any tools related to automating (or semi-automating) the screening process of systematic reviews or meta-analyses of aging and longevity research was reported.

### **Our Contribution**

- Present a simple machine learning framework that can be used in the screening stage of systematic reviews or meta-analyses of aging and longevity research studies.
- Present our experimental results on dataset related to Dasatinib and Quercetin Senolytic Therapy Risk-Benefit Analysis<sup>1</sup>(D&Q Analysis).

5/16

<sup>&</sup>lt;sup>1</sup>The analysis is part of "Rejuvenation Now" non-profit initiative that: "seeks to continuously identify potential rejuvenation therapies and systematically evaluate their risks, benefits, and associated therapeutic protocols to create transparency" published by Forever Healthy Foundation

### **Outline**




Figure 2: Technical Overview.

#### **Features**

#### Extracted features are based on:

- Provided list of search terms: dasatinib, senolytic, senescent, ...
- Possible publication types: case report, clinical trial, review, ...
- TF-IDF scores of terms: chronic myeloid, adverse event, tyrosine kinase, ...
- LDA model probabilities of belonging to topics:

#### Topic Terms

- trial, clinic, efficaci, report, safeti, assess, evalu, show, advers, ...
- 2. week, placebo, treatment, group, extract, symptom, score, patient, hypericum, ...
- 3. dasatinib, patient, case, treatment, report, chronic, leukemia, therapi, myeloid, ...
- 4. cvd, risk, cardiovascular, prevent, factor, profil, diseas, lipid, import, ...
- 5. flavonoid, anthocyanin, individu, adult, genistein, dietari, isoflavon, flavanon, intak, ...
- 6. sunitinib, sorafenib, target, imatinib, includ, cancer, erlotinib, anticanc, malign, ...
- 7. bone, marrow, chromosom, abnorm, deriv, prognost, signific, aberr, delet, ...
- 8. lifespan, elegan, longev, stress, effect, life, span, extend, increas, ...
- 9. muscl, smooth, vsmc, skelet, aortic, havsmc, resist, accordingli, folfiri, ...
- 10. quercetin, effect, cell, concentr, human, dose, depend, studi, increas, ...

4 D > 4 A P > 4 B > B + 9 Q P

• • •

### Model

- Used L1 regularized logistic regression model from scikit-learn.
- Fitted using Liblinear solver with balanced class weights.
- Placed more emphasis on recall by using recall scorer.


### Definition (Relevance)

The model estimates the conditional probability, called *relevance score*, that a given document d is relevant given feature vector  $X^d$ :

 $Pr(d \text{ is relevant}|X^d)$ 

# **Threshold Selection**


The selected cut-off threshold for D&Q Analysis was 0.26 where the binary classifier achieved 95% recall:



9/16

#### **Errors**

There are four possible outcomes of comparing the classification result with human assigned label:



### **Performance Evaluation**

Performance was assessed by:

### Definition (Statistical measures)

Precision P is the fraction of documents labeled as relevant among documents classified as relevant:

$$P = \frac{TP}{TP + FP}$$

Recall R (also known as *sensitivity*) is the fraction of documents labeled as relevant that were also classified as relevant:

$$R = \frac{TP}{TP + FN}$$

Work Saved over Sampling WSS@R is the reduction of documents that need to be screened compared to a random ordering of the documents to achieve a level of recall R:

$$WSS@R = \frac{TN + FN}{N} - (1 - R)$$



### **Evaluation Results**

| Fold | Recall      | Precision  | PR-AUC      | WSS@R       |
|------|-------------|------------|-------------|-------------|
| 1    | 0.94        | 0.13       | 0.54        | 0.53        |
| 2    | 0.90        | 0.16       | 0.33        | 0.61        |
| 3    | 1.00        | 0.14       | 0.48        | 0.63        |
| 4    | 0.94        | 0.19       | 0.54        | 0.67        |
| 5    | 0.97        | 0.20       | 0.43        | 0.71        |
| Mean | 0.95 (0.03) | 0.17(0.03) | 0.46 (0.08) | 0.63 (0.06) |

Table 1: Summarized results of 5-fold cross-validation for D&Q Analysis

### **Evaluation of Results**




Figure 3: Visualized results of 5-fold cross-validation for D&Q Analysis

13 / 16

Marko Lalović Longevity Research Screening March 10,

### **Export**

#### Results for Dasatinib and Quercetin Senolytic Therapy Risk-Benefit Analysis

|  |                   | New Articles                                       | False Negatives             | False Positives                     |                            |        |                |  |
|--|-------------------|--|-----------------------------|-------------------------------------|----------------------------|--------|----------------|--|
|  | Te                | able 2: Estimated Relevance for False Negatives un | il 17. April, 2020 included | in the Risk-Benefit Analysis but no | ot classified as relevant. |        |                |  |
| Relevance  | Date              | Title  |                             | Abstract                            |                            | Expand | URL            |  |
| 0.3  | 22. März, 2013    | Bioavailability of quercetin: problems and pr      | omises Que                  | ercetin (QC) is a typical plant fla | vonoid, possesses d        | +      | pubmed         |  |
| 0.29   | 1. Januar, 2005   | Cytotoxicity of flavonoids toward cultured n       | ormal hum The               | cytotoxicity of flavonoids, inclu   | iding apigenin, erio       | +      | pubmed         |  |
| 0.25   | 6. Februar, 2016  | Association Between BCR-ABL Tyrosine Ki            | nase Inhib Imp              | ortance: A phase 3 trial with por   | natinib in patients        | +      | pubmed         |  |
| 0.24   | 22. August, 2016  | Targeting Pro-Inflammatory Cells in                | Idiopathic Pulmonary F      | ibrosis: a Human Trial (IPF)        |                            | Zhu) - | clinicaltrials |  |
| The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days in 3 consecutive weeks) and administration of combination Dasatinib (100 mg/d) + Quercetin (1250 mg/d) will be safe and well tolerated in patients with PF. Treatment with D+Q will result in reduced abundance of pro-inflammatory cells within subjects over baseline. Finally, the reduction in biomarkers of cellular pro-inflammatory state will be related to no change in functional and patient reported outcomes. |                   |  |                             |                                     |                            |        |                |  |
| 0.22   | 19. Januar, 2017  | Identification of cellular targets involved in o   | ardiac fail Air             | ns: The aims of the present study   | were to evaluate t         | +      | pubmed         |  |
| 0.22   | 3. Oktober, 2017  | Short-term High Dose of Quercetin and Resv         | eratrol Alt Bao             | kground: Hyperglycemia-media        | ted oxidative stress       | +      | pubmed         |  |
| 0.22   | 14. Februar, 2018 | BCR-ABL Tyrosine Kinase Inhibitors: Which          | h Mechani Ima               | tinib, the first-in-class BCR-AB    | L tyrosine kinase in       | +      | pubmed         |  |
| 0.19   | 1. Januar, 2008   | Quercetin pharmacokinetics in humans               | The                         | purpose of this study was to exa    | amine the pharmac          | +      | pubmed         |  |
| 0.18   | 6. Mai, 2009      | Tyrosine kinase inhibitor-induced platelet dy      | sfunction i Das             | atinib is associated with increase  | ed risk of bleeding        | +      | pubmed         |  |
| 0.18   | 17. März, 2004    | Quercetin, an over-the-counter supplement, or      | auses neur A 2              | 2-month-old boy, who regularly      | consumed the oral          | +      | pubmed         |  |
| nge: 1 2   |                   |  |                             |                                     |                            |        |                |  |

Last updated: Do 25. Feb 11:38:01 CET 2021

Figure 4: Interactive tables of exported documents for D&Q Analysis.

### Links

- Interactive tables of exported documents for D&Q Analysis: https://markolalovic.com/longevity-research-screening/
- Technical report: TODO
- Source code:

https://github.com/markolalovic/longevity-research-screening/

#### References

- Bannach-Brown, A., Przybyła, P., Thomas, J. et al. "Machine learning algorithms for systematic review: reducing workload in a preclinical review of animal studies and reducing human screening error.", Syst Rev 8, 23 (2019). https://doi.org/10.1186/s13643-019-0942-7
- Howard BE, Phillips J, Miller K, et al. "SWIFT-Review: a text-mining workbench for systematic review.", Syst Rev. 2016;5:87. Published 2016 May 23. doi:10.1186/s13643-016-0263-z
- O'Mara-Eves, A., Thomas, J., McNaught, J. et al. "Using text mining for study identification in systematic reviews: a systematic review of current approaches.", Syst Rev 4, 5 (2015). https://doi.org/10.1186/2046-4053-4-5
- Przybyła P, Brockmeier AJ, Kontonatsios G, et al. "Prioritising references for systematic reviews with RobotAnalyst: A user study.", Res Synth Methods. 2018;9(3):470-488. https://doi.org/10.1002/jrsm.1311
- Wallace, B.C., Trikalinos, T.A., Lau, J. et al. "Semi-automated screening of biomedical citations for systematic reviews.", BMC Bioinformatics 11, 55 (2010). https://doi.org/10.1186/1471-2105-11-55